What Diosper Treats: Main Uses and Benefits

Diosper is generally used in areas where additional symptomatic support is needed to manage the symptoms related to physical discomfort associated with conditions marked by increased physiological stress. This phlebotropic agent is commonly used in clinical settings that involve acute or unstable symptom patterns, with primary uses across conditions presenting with significant symptomatic burden, including Chronic Venous Insufficiency (CVI), Varicose Veins, and Acute Hemorrhoidal Disease.

Diosper is relevant for easing distress associated with venous conditions. It helps address symptom clusters that may become intense or disruptive, such as the persistent feeling of heavy legs, venous pain, nocturnal cramps, and localized swelling (edema).

This therapeutic application contributes to easing the overall symptom load during symptomatic periods. In situations where patients experience heightened discomfort, such as during a flare-up, Diosper may support patients by helping to ease distress and provides supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Symptomatic support is provided for Chronic Venous Discomfort and Acute Hemorrhoidal Swelling.

Regulatory References

1. Philippines FDA Verification Portal (Venacure)

Contraindications and Restrictions

Eligibility for Diosper (Diosmin and Hesperidin) is strictly defined by regulatory authorities, outlining populations that may use the medicine and those who are formally restricted or prohibited.

Classification	Eligibility Rule (Official Labeling)
Absolute Contraindication	Individuals with known hypersensitivity or allergy to the active substances (Diosmin, Hesperidin, or MPFF) or any of the inactive ingredients.
Approved Population	Adults (typically ge 18 years of age) for whom dosing instructions are provided.
Pediatric Restriction	Not Recommended for children and adolescents (under 18 years). Safety and efficacy have not been established in this age group by regulators.
Pregnancy Status	Avoidance is preferable as a precautionary measure due to limited or insufficient clinical data from its use in pregnant women.
Lactation Status	Inadvisable for the duration of treatment, due to the absence of data regarding the excretion of the active substance or its metabolites into human milk.

Official regulatory documents do not generally specify formal non-eligibility rules related to defined stages of hepatic (liver) or renal (kidney) impairment.

Interactions with other medicines and products

Interaction Type	Official Regulatory Status
Contraindicated Combinations	None listed due to interaction risk
Pharmacokinetic/Pharmacodynamic	None reported or formally studied
Timing Requirements	No mandatory separation rules documented
Food / Alcohol / Herbal Products	Food interaction listed as "Not applicable"

---

The official regulatory interaction profile for this medicine is defined by limited documented information regarding co-administration with other substances. Some government prescribing information notes that formal drug-interaction studies have not been performed, and post-marketing surveillance reports an overall absence of clinically relevant drug interactions. This absence means official regulatory documents do not list any specific medicinal products that are formally contraindicated for co-administration due to interaction risk, nor are there any mandatory timing separation requirements for doses.

There are no documented interactions involving common metabolic pathways, such as CYP enzymes, or with major drug transporters. While the overall profile suggests minimal known interactions, certain regulatory patient information leaflets explicitly advise users to inform their healthcare provider if they are currently taking diclofenac (an anti-inflammatory medicine) or fexofenadine (a cold and allergy medicine). This requirement is solely for precautionary monitoring. Furthermore, official regulatory documents state that an interaction with food is not applicable, and no specific restrictions concerning alcohol or herbal product interactions are documented. This structure confirms that the known interaction constraints are primarily limited to precautionary steps for two specific medicinal products rather than general prohibitions.

Targeted Control of Cellular Inflammation and Oxidative Stress

Diosper's active metabolite, diosmetin, acts as a dual modulator of cellular signaling. It influences the inflammatory response by inhibiting the transcription factor NF-kappaB, which regulates the production of pro-inflammatory mediators. Simultaneously, it activates the Nrf2 pathway, thereby increasing the cell's endogenous production of antioxidant enzymes. This molecular modulation results in decreased production of inflammatory mediators and increased ROS scavenging capacity.

---

Modulation of Venous Tone and Microvascular Permeability

The mechanism promotes the contraction of venous smooth muscle, resulting in an increase in venous tone. It also influences the vascular endothelium, causing a decrease in capillary permeability across the microvascular wall. These physiological adjustments modulate circulatory dynamics by increasing resistance in the venous compartment and altering fluid dynamics.

---

Influence on Cellular Integrity and Apoptosis

Diosper engages mechanisms that influence cell survival by inhibiting caspases, which are enzymes central to programmed cell death or apoptosis. It also modulates protective signaling pathways such as Akt and PPAR-gamma. This molecular influence on caspase activity supports the preservation of cellular integrity in the context of persistent stress.

How to Use Diosper: Official Administration Guidelines

Diosper is administered exclusively via the oral route as a tablet containing the micronized purified flavonoid fraction (MPFF). The official usage protocols establish distinct dosing and duration patterns based on the condition being addressed.

---

Standard Dosage Patterns

The administration schedule is defined by two key scenarios. For long-term use associated with chronic venous symptoms, the standard adult regimen is a daily dose of 1000 mg of MPFF. This daily amount may be administered as a single dose or in divided use across the day.

Conversely, the use for acute hemorrhoidal episodes is defined by a short-term, high-dose course lasting a total of 7 days. This regimen requires a loading phase of 3000 mg MPFF daily for the initial four days, followed by a tapering phase of 2000 mg MPFF daily for the subsequent three days.

---

Administration Conditions and Timing

Proper use requires that the medicine be taken at mealtimes (i.e., alongside food). The tablets must be swallowed whole with a glass of water, as no further preparation or dilution is specified. The instructions strictly define the daily administration pattern for the 7-day acute course as a divided daily use.

Age-Group Use

Official prescribing information restricts the use of Diosper based on age. Dosage and administration patterns have not been established for the paediatric population, which includes children and adolescents under 18 years of age. Therefore, the established protocols are applicable only to adult individuals.

Research evidence / Overview of Studies for Diosper

Evidence for Symptom Management in Chronic Venous Disorders (CVD)

The research base for Diosper relevant to the study of Chronic Venous Disorders (CVD), conditions which involve symptoms like leg heaviness and pain, primarily involves short- to intermediate-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time by comparing the compound against a placebo or other active treatments. Research explored patient-reported outcomes that included measurements of leg pain, heaviness, and nighttime cramps, which are all outcomes related to physical discomfort in conditions marked by functional limitations.

The studies focused on adult populations, including those with varying degrees of venous disease severity. Research highlights changes measured during the study period, reporting how symptoms evolved in the observed populations over typical trial durations, which ranged from a few weeks up to six months. Findings describe patterns observed in the studies related to changes in patient-reported symptom measurements. Furthermore, research explored objective measurements, such as changes in leg swelling (edema) volume.

Evidence is limited for long-term outcomes and the persistence of the changes tracked in the studies beyond the six-month follow-up period in most primary trials. There is also limited comparative evidence available to fully characterize how this specific micronized purified flavonoid fraction (MPFF) compares against other pharmacological options studied for the management of CVD symptoms. Certainty remains low for some objective physical endpoints, as some scientific reviews note variability in the findings reported across the included studies.

Evidence for Acute Hemorrhoidal Episodes

For Acute Hemorrhoidal Disease, research was studied for episodes where symptoms become more noticeable. Studies explored the compound's use during periods of heightened symptom activity, such as acute pain, bleeding, and swelling. This evidence is primarily derived from short-term RCTs which often compared the compound to a placebo or observed its use alongside standard local care during the symptomatic crisis.

These trials were relevant in evidence describing how symptoms are measured for outcomes describing episodic or acute changes. Studies monitored the rapid resolution of key patient-reported outcomes describing perceived discomfort, including pain and bleeding intensity, as well as clinician-assessed changes in objective signs like swelling and prolapse. Findings describe patterns observed when studies examined symptom intensity over the short-term treatment period, typically lasting 7 to 12 days. The research provides insight into short-term changes for conditions characterized by fluctuating or episodic manifestations.

Key Studies & References

1. Efficacy and tolerability of micronized purified flavonoid fractions (MPFF) for haemorrhoids: A systematic review and meta-analysis
2. CEAP classification of severity of varicose veins (describes C0-C6 severity used in studies)
3. WHO ATC Code C05CA03 (Diosmin Classification)

Common questions about Diosper (FAQ)

Q: What is Diosper used for?

A: Diosper (Diosmin) is primarily used to help with conditions related to poor blood circulation in the veins, particularly in the legs. This includes:

• Chronic Venous Insufficiency (CVI): A condition where blood pools in the legs due to weakened vein walls and valves. Diosper can help reduce symptoms such as leg pain, heaviness, cramping, and swelling.
• Hemorrhoids: Diosper can be used for the symptomatic treatment of acute and chronic hemorrhoids to help relieve symptoms like bleeding, pain, and itching.

Q: How does Diosper work?

A: Diosper is classified as a venotonic and vasculoprotective agent. It works by affecting the walls of your blood vessels. Specifically, it:

• Increases venous tone: This helps to reduce the stretching of the veins and makes them narrower, improving blood flow back toward the heart.
• Reduces inflammation: It helps reduce the inflammation and swelling of the veins.
• Protects capillaries: It helps to protect the smallest blood vessels (capillaries) from damage.

By these actions, Diosper helps decrease vein pressure and improves the circulation of blood and fluid (lymph) in the affected areas.

Q: What are the common side effects of Diosper?

A: Diosper is generally well-tolerated. However, like all medications, it can cause side effects. The most frequently reported side effects are usually mild and related to the stomach and digestion. These include:

• Stomach pain or discomfort
• Diarrhea
• Nausea or vomiting

Other less common side effects can include:

• Headache
• Dizziness
• Rash or itching

If you experience any severe side effects or allergic reactions (such as swelling of the face, lips, tongue, or throat, or difficulty breathing), you should stop taking the drug and seek immediate medical attention.

Q: Can Diosper interact with other medications?

A: Yes, Diosper may interact with certain other medications. It is important to tell your doctor or pharmacist about all the medications, supplements, and herbal products you are taking. Diosper may affect how some medications are broken down by the liver or absorbed by the body. These potential interactions include those with:

• Certain blood-thinning medications (anticoagulants), which could increase the risk of bleeding.
• Some non-steroidal anti-inflammatory drugs (NSAIDs), which may increase their effects or side effects.
• Certain anticonvulsant and antihistamine medications.

Your healthcare provider can assess your full medication list and advise if any dosage adjustments or extra monitoring are necessary.

Storage Guidelines

Diosper should be stored at room temperature away from excess heat, moisture, and direct light, such as outside of a bathroom or kitchen cabinet where humidity can fluctuate. Always keep the medication in its original container and ensure the container is tightly closed. It must be stored out of sight and reach of children and pets.

Never use this medication if it has expired or if you notice any changes in its color or consistency.

---

Disposal Guidelines

The safest way to dispose of unwanted or expired Diosper is to return it to a drug take-back program or a local pharmacy that accepts unused medications. Do not flush the medication down the toilet or pour it down a drain unless the product packaging specifically instructs you to do so, as this can contaminate the environment. If a take-back program is not available, mix the medication with an unappealing substance, such as dirt or used coffee grounds, seal it in a plastic bag, and then dispose of it in your household trash. Scratch out all personal information on the prescription label before disposal.